Avalon Completes Non-Brokered Private Placement  for Gross

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avalon Completes Non-Brokered Private Placement  for Gross Proceeds of $1 Million

TORONTO, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Avalon Advanced Materials Inc. ( TSX :AVL) ( OTCQX :AVLNF) (“Avalon” or the “Company”) is pleased to announce that it has completed a non-brokered private placement today consisting of 4,545,454 flow-through shares at a price of $0.22 per share for gross proceeds of $1,000,000.

In conjunction with this private placement Avalon paid finder’s fees of $60,000 and issued 272,727 non-transferrable finder’s warrants, with each finder’s warrant being exercisable to acquire one common share of the Company at a price of $0.25 for a period of 24 months from today. Pursuant to Canadian securities laws, the securities issuable under this private placement are subject to a hold period which expires on March 8, 2017. The proceeds from this offering will be used primarily to advance exploration work, including drilling, on the Company’s Separation Rapids Lithium Project. This press release is not an offer of securities for sale in the United States. The securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”), and may not be offered or sold in the United States or to US persons (as defined in Regulation S under the US Securities Act) absent registration or an applicable exemption from registration.

About Avalon Advanced Materials Inc. Avalon Advanced Materials Inc. (formerly Avalon Rare Metals Inc.) is a Canadian mineral development company specializing in niche market metals and minerals with growing demand in new technology. The Company has three advanced stage projects, all 100%-owned, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, niobium, and zirconium. Avalon is currently focusing on its Separation Rapids Lithium Project, Kenora, ON and its East Kemptville Tin-Indium Project, Yarmouth, NS. Social responsibility and environmental stewardship are corporate cornerstones.

For questions and feedback, please e-mail the Company at ir@AvalonAM.com , or phone Don Bubar, President & CEO at 416-364-4938.

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements related to how the Company plans to use the net proceeds from the Private Placement , and that proceeds from this offering will be used primarily to advance exploration work, including drilling, on the Company’s Separation Rapids Lithium Project. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “potential”, “scheduled”, “anticipates”, “continues”, “expects” or “does not expect”, “is expected”, “scheduled”, “targeted”, “planned”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be” or “will not be” taken, reached or result, “will occur” or “be achieved”. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avalon to be materially different from those expressed or implied by such forward-looking statements. Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made. Although Avalon has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to market conditions, and the possibility of cost overruns or unanticipated costs and expenses as well as those risk factors set out in the Company’s current Annual Information Form, Management’s Discussion and Analysis and other disclosure documents available under the Company’s profile at www.SEDAR.com . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Such forward-looking statements have been provided for the purpose of assisting investors in understanding the Company’s plans and objectives and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking statements. Avalon does not undertake to update any forward-looking statements that are contained herein, except in accordance with applicable securities laws.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 228

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 73

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading
AWS Boosts Agilix's AI Education in Sierra Leone

Updated Category News Views 21

Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 124

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 119

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Ericsson Buybacks: Strategic Moves or Market Maneuver?

Updated Category News Views 10

Breaking Down Ericsson's Strategic Share Buybacks When a company like Ericsson starts pulling stocks off the shelves like they're on sale, it's time to take notice. Between November 2nd and 6th, Ericsson, that telecom giant we all know, went on a little shopping spree, snapping up 500,000 of its own Class B shares. Why should we care? Well, it's a part of their hefty SEK...

Continue Reading
Inside Kristallnacht: An XR Journey for a New World

Updated Category News Views 67

Bridging the Past with Powerful Tech: A Journey to Kristallnacht Let's cut to the chase: if there's a time in history that we all need to sear into our collective consciousness, it's Kristallnacht. Forget the mere notion of reading it from a textbook; now you can dive headfirst into the harrowing events of November 9, 1938, thanks to the cutting-edge initiative inside...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 481

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading

Top 5 Most Recently Viewed Articles

TC BioPharm's Continued Trading Highlights Market Confidence

Updated Category News Views 156

TC BioPharm Continues to Trade On Nasdaq TC BioPharm (Holdings) PLC, recognized by the ticker symbol TCBP, is actively trading on the Nasdaq Global Select Market. This clinical-stage biotechnology company is notably focused on developing allogeneic gamma-delta T cell therapies, primarily targeting cancer and various other medical conditions. Sustained Trading Activity The...

Continue Reading
Innovative AI Partnership Enhances Retail Security Solutions

Updated Category News Views 65

RaptorVision and Veesion Unite for Retail Excellence In a significant development for the retail industry, RaptorVision and Veesion have announced a global strategic partnership. This collaboration merges Veesion’s advanced concealment detection behavioral analytics with RaptorVision’s AI Event-Based Product Engagement and Integration Platform tailored for the retail...

Continue Reading
ADM's Q2 2025 Financial Performance: Insights and Trends

Updated Category News Views 152

ADM's Financial Overview for Q2 2025 ADM Aéroports de Montréal has released its financial results for the second quarter of 2025. This comprehensive report encompasses passenger traffic data, revenue figures, and insights into ongoing capital investment projects at YUL Montréal-Trudeau International Airport. Key Highlights of the Q2 Results The second quarter of 2025...

Continue Reading
Octopus AIM VCT Welcomes New Non-Executive Director

Updated Category News Views 184

Octopus AIM VCT Announces a Strategic Appointment Octopus AIM VCT plc is thrilled to share the exciting news of David Docherty joining the team as an independent Non-Executive Director. His official start will follow the upcoming Annual General Meeting. This strategic move reflects the company's commitment to enhance its governance and leadership. A Wealth of Experience...

Continue Reading
Enhancing Cybersecurity: New Designation for Risk Management Pros

Updated Category News Views 177

Introducing the Associate in Cyber Risk Management Designation In today's digital age, cyber risks have become one of the most pressing challenges for organizations globally. An alarming number of C-level executives—87% according to a recent survey—acknowledge that their companies are not fully prepared to face potential cyberattacks. Recognizing this critical issue,...

Continue Reading